文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than
侵权投诉

Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than

168Retinal,vitreousandmaculardisorders

retinalcapillaryblood ow,retinalandvitreoushemor-rhage,reducedvisualacuity,andultimately,blindness.

Proliferativediabeticretinopathy

VEGFisoneofmanyproin ammatorymoleculesimpli-catedintheearlystagesofdiabeticretinopathy,evenbeforeitenterstheproliferative(PDR)stage[38],andtheuseofanti-VEGFagentshasshownpotentialasatreatmentoptionforPDRaswellasDME.PegaptanibsodiumisaPEGylated28-nucleotideaptamerthatspeci callytargetstheVEGF-165isoform(Table2).IthasbeenevaluatedasanadjuncttherapyinPDRrefrac-torytolasertreatmentandassociatedwithdecreasedretinalthickness,reductioninleakageandvitreoushemorrhage,andsomebene cialeffectonvisualacuity[39,40].However,theseweresmall(n¼5–13)retrospec-tivestudiesthatusedvarioustreatmentregimens,andrequirecon rmationinlarger,prospective,randomizedtrials.Aretrospectiveanalysisofarandomized,controlledclinicaltrialevaluatingpegaptanibfortreatmentofDMEshowedthatof16patientswithretinalneovasculariza-tion,eightof13(62%)whoreceivedpegaptanib(threeinjectionsof0.3,1,or3mgover12weeks),whereasnoneofthethreepatientsintheshamgroupshowedeitherregressionofneovascularizationonfundusphotographsorregressionorabsenceof uoresceinleakagefromneovascularization(orboth)at36weeks[41].

Anumberofcasestudieshavedemonstratedthatoff-labelintravitrealbevacizumabcancauseregressionofneovascularizationintheiris,disc,andretina,andreducevascularleakageassociatedwithdiabeticretinopathy[42–46].Aninterventionalcaseseriesstudyevaluatedbevacizumab(1.25mg)in19patientswithperipheralretinalischemiaindiabeticretinopathy[47].At1-monthfollow-up,visualacuityhadimproved(P¼0.08),andtherewasangiographicevidenceofasigni cantdecreaseinmeanperipheralretinalischemiaattheearlyphase(P¼0.02)andlatephase(P<0.001),althoughnochangewasnotedinretinalthicknessmeasuredbyopticalcoher-encetomography(OCT).TheseresultsindicatedthatbevacizumabmaybeaviabletreatmentoptionforretinalischemiainPDR.Theef cacyofintravitrealbevacizu-mabinPDRiscurrentlybeingevaluatedinaphaseIIInonrandomized,open-label,uncontrolledclinicalstudyinIranandaphaseII/IIIrandomized,open-label,con-trolledclinicalstudyinMexico.

Diabeticmacularedema

Apilotstudyofmonthlyintravitrealranibizumab(0.3or0.5mg)demonstratedthatranibizumabcanreducecen-tralretinalthicknessandincreasevisualacuityinDME.Atmonth3,ranibizumabhadimprovedvisualacuitybyatleast15lettersin40%andbyatleast10lettersin50%ofpatients[49].Inanonrandomizedtrialinvolving10patientswithDME,0.5mgranibizumabwasinjectedintravitreallyatmonths0,1,2,4,and6(atotalof veinjectionsperpatient)[50].At7months(1monthafterthe fthinjection),themedianandmeanreductionsinexcessfovealthicknesswere261and246mm,respect-ively(an85%reductioncomparedwithbaseline;P¼0.005).Themacularvolumewas7.47mm3,reducedby1.75mm3(77%oftheexcessmacularvolumeatbase-line;P¼0.009).Meanvisualacuitywas40.4letters(20/40),animprovementof12.3letters(P¼0.005).Theinjectionswerewelltolerated,withnoocularorsystemicadverseevents[50].Tworandomized,double-masked,placebo-controlledphaseIIIstudiesofranibizumabinDMEwithcenterinvolvement[studyofranibizumabinjectioninsubjectswithclinicallysigni cantmacularedemawithcenterinvolvementsecondarytodiabetesmellitus(RISE),ranibizumabinjectioninsubjectswithclinicallysigni cantwithmacularedema.centerinvolve-mentsecondarytodiabetesmellitus(RIDE)arecur-rentlyongoing[51].

Aconsecutivecaseseriesstudyof10eyesshowedthat1monthafterthreeinjectionsofbevacizumab(1mgevery6weeks),therewasagainofatleast10lettersin40%ofeyes,alongwithareductioninmeanfovealthicknessof45mm,butwithoutnormalizationoffovealandmacularthickness[52 ].Aprospective,placebo-controlled,ran-domizedclinicaltrialevaluatedbevacizumab(threeinjectionsof1.25mgat6-weekintervals)eitherasmono-therapyorincombinationwithintravitrealtriamcinoloneacetonidein115eyesin101patientswithrefractoryDME[53 ].Atweek24,centralmacularthickness(CMT)measurementsbyOCTweresigni cantlyreducedwithbevacizumabmonotherapy(meanchangeofÀ95.7mm)andwithcombinationtherapy(meanchangeofÀ92.1mm);thesechangesweresigni cantwhencomparedwithachangeofþ34.9mmintheshamcontrolgroups(monotherapy,P¼0.012;combinationtherapy,P¼0.022).Signi cantgainsinvisualacuitywerealsonotedcomparedwiththecontrolgroup(mono-therapy,P¼0.01;combinationtherapy,P¼0.006).Theadditionoftriamcinoloneinthisstudyhadnosigni canteffectonanatomicresults,butdidresultinatrendtowardearliervisualimprovements.Similaroverallresultswerealsofoundinanotherrandomizedstudy[54].Asimilarprospective,longitudinalcaseseriesdemonstratedthateveninpatientswithchronicdiffuseischemicDME(N¼126),treatmentwithintravitrealbevacizumab(1.25mg)reducedthemeanCMTby89and106mmafter6and12months,respectively(P<0.001forboth),

InaphaseIItrialofpatientswithDME,0.3mgpegap-tanibsodiumtherapyadministeredevery6weeks(threetosixtotalinjections)resultedinsigni cantlybettergainsinvisualacuity(34versus10%!10-lettergain;P¼0.003)andsigni cantlygreaterdecreasesincentralretinalthick-nesscomparedwithshamtreatment(68versus4mmdecrease;P¼0.02)[48].

上一页第3页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email